Imatinib which is introduction of the first TKI, into clinical practice after IRIS trial 13 , has dramatically changed treatment and follow-up of CML. 1, 13 TKIs specifically targets tyrosine kinase activity of the oncogenic protein encoded by bcr/abl gene. Currently, two more powerful second generation TKIs are available for clinical management of CML, namely dasatinib 14 and nilotinib. 15 The European LeukemiaNet (ELN) 2009 recommendations have placed second generation TKIs for the second-line treatment of imatinib-intolerant or imatinib-resistant CML. 16 Based on the ELN 2009 recommendations; "Continue imatinib same dose; or test high dose imatinib..." was suggested as a treatment for "imatinibsuboptimal responders". High dose imatinib, which had inferior efficacy when compared to dasatinib and nilotinib, is not superior to standard dose imatinib too. 19 Increased ratio of complete cytogenetic response (CCyR) and faster, earlier, deeper, durable, more common sustained major molecular response (MMR) obtained via second generation TKIs prompted the earlier administration of dasatinib or nilotinib during the clinical course of CML. More powerful TKIs shall be given at the earlier sign(s) of resistance and/or intolerance to frontline imatinib. 20 The elucidation of the superiority of frontline dasatinib or nilotinib could be possible with the upcoming three-year follow-up of the DASISION 14 and ENESTnd 15 trials.
Current optimal targets based on ELN 2009 in a chronic phase (CF) CML patient receiving imatinib is the occurrence of complete hematological remission (CHR) within 3 months, partial cytogenetic response (PCyR) at 6 months, CCyR at 12 months, and MMR at 18 months. 8 More powerful TKIs, dasatinib and nilotinib should be administered at the earlier stage if imatinib fails to produce those responses in these critical time points. 20 On the other hand, if second generation TKIs would be the frontline treatment for CF-CML patient, the ideals could be CHR within 3 months, CCyR at 6 months, MMR at 12 months, and CMR at 24 months. However, the follow-up period of frontline dasatinib and nilotinib studies are relatively short. Therefore, presently in 2011 the most practical follow-up guidelines have been established by Kantarjian and Cortes from MD Anderson Cancer Center. 20 Their recommendations are depicted in Table 1 . Today, the best way for treatment of CF CML is tyrosine kinase inhibition and the best follow-up of the CML patient with appropriate essential interventions.
In this supplementary issue of UHOD, the selections of second generation TKIs 21 , their long-term adverse effects with proper follow-up and management 22 , treatment of advanced-phase CML with focus on transplantation 23 , and current problems in the management of chronic myeloid leukemia in Turkey 24 have been summarized. Near future holds promise for the better CML management, operational cure of CML, or even cure of the disease with the discontinuation of TKI and/or targeting CML stem cell.
